Titre : | Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses (Review) (2023) |
Auteurs : | N. LINDSON ; A. THEODOULOU ; J. M. ORDONEZ-MENA ; T. R. FANSHAWE ; A. J. SUTTON ; J. LIVINGSTONE-BANKS ; A. HAJIZADEH ; S. ZHU ; P. AVEYARD ; S. C. FREEMAN ; S. AGRAWAL ; J. HARTMANN-BOYCE |
Type de document : | Article : Périodique |
Dans : | Cochrane Database of Systematic Reviews (n°9, 2023) |
Article en page(s) : | art. CD015226 |
Langues: | Anglais |
Discipline : | TRA (Traitement et prise en charge / Treatment and care) |
Mots-clés : |
Thésaurus mots-clés ARRET DU TABAC ; TABAC ; SEVRAGE ; E-CIGARETTE ; ADULTE ; INTERVENTION ; PHARMACOTHERAPIE ; NICOTINE ; VARENICLINE ; COMPARAISON ; EFFICACITE ; SUBSTITUTS NICOTINIQUES ; BUPROPION |
Résumé : |
Key messages:
Some medicines and e-cigarettes (handheld devices that work by heating liquid that usually contains nicotine and flavourings) can help people to quit smoking for six months or longer. E-cigarettes, and the medicines cytisine (otherwise known as Tabex) and varenicline (otherwise known as Chantix and Champix), appear to help the most people to quit smoking, followed by using two types of nicotine replacement therapy at once (nicotine patch and another type, such as gum or lozenge). We need more evidence on possible long-term harms of e-cigarettes and medicines to help people quit smoking, but there were very low numbers of serious harms found. Stopping smoking: Tobacco smoking is bad for people's health and stopping can lead to significant improvements. Most people would like to quit smoking and there are medicines and e-cigarettes available to help people to do that. These medicines are called nicotine replacement therapy, cytisine, varenicline, bupropion (sometimes known as Zyban or Wellbutrin) and nortriptyline (sometimes known as Norpress). Nortriptyline is only available for quitting smoking in New Zealand, and cytisine is not available in many countries. At time of writing, there are shortages of varenicline due to a manufacturing issue. These medicines and e-cigarettes can be provided alongside behavioural support, such as counselling. Stop smoking medications and e-cigarettes are designed to reduce people's craving to smoke. By finding out more information on how these treatments compare to each other, we hope this review will be used to decide the best treatments to help people stop smoking. Why we did this Cochrane Review: We wanted to find out: - which treatments (medicines and e-cigarettes) help people to stop smoking; - how these treatments compare to each other; - whether there are ways of providing these treatments that mean they are more likely to help people stop smoking (e.g. different doses or treatment lengths); - whether these treatments are likely to cause serious harms; and - whether certain treatments are better tolerated, as indicated by fewer people leaving a study due to treatment. What are the main results of our review? E-cigarettes, varenicline and cytisine were most likely to help people quit smoking. For every 100 people, 10 to 19 are likely to quit using an e-cigarette; 12 to 16 using varenicline; and 10 to 18 using cytisine. This is compared to the 6 in 100 people likely to quit when using no medicine/e-cigarette or placebo. People using two forms of nicotine replacement therapy at the same time, for example, a combination of nicotine patch and nicotine gum, seemed to have similar rates of quitting to people using e-cigarettes, varenicline and cytisine. Nicotine patches alone, another form of nicotine replacement therapy alone (such as gum, lozenge) and bupropion appeared to help fewer people quit but still work better than no medicine/e-cigarette or placebo (8, 9 and 9 people per 100, respectively). Nortriptyline appeared to result in the lowest number of people quitting smoking; for every 100 people using nortriptyline 6 to 11 are likely to quit. We are moderately confident that bupropion could rarely cause some serious health effects. The information we have for other treatments does not provide clear evidence of serious harms. For all treatments, findings suggest very few people experience serious harms when using them. |
Domaine : | Tabac / Tobacco / e-cigarette |
Sous-type de document : | Méta-analyse / Meta-analysis ; Revue de la littérature / Literature review |
Affiliation : |
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK Department of Health Sciences, University of Leicester, Leicester, UK Department of Respiratory Sciences, University of Leicester, Leicester, UK |
URL : | JAMA Medical News in Brief (27/09/2023) ; EurekAlert! (12/09/2023) |
Lien : | https://doi.org/10.1002/14651858.CD015226.pub2 |
Accueil